This company listing is no longer active
OKYO Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
OKYO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.91 |
| 52 Week High | UK£3.90 |
| 52 Week Low | UK£0.88 |
| Beta | -0.062 |
| 1 Month Change | -9.68% |
| 3 Month Change | -65.69% |
| 1 Year Change | -63.64% |
| 3 Year Change | -45.10% |
| 5 Year Change | n/a |
| Change since IPO | -98.13% |
Recent News & Updates
Recent updates
Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?
Nov 26
Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?
Jan 27Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation
Sep 22We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth
Mar 17We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow
Dec 02Shareholder Returns
| OKYO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -31.7% | 0.1% | 0.9% |
| 1Y | -63.6% | -14.2% | 0.7% |
Return vs Industry: OKYO underperformed the UK Biotechs industry which returned -16.5% over the past year.
Return vs Market: OKYO underperformed the UK Market which returned -2.2% over the past year.
Price Volatility
| OKYO volatility | |
|---|---|
| OKYO Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: OKYO's share price has been volatile over the past 3 months.
Volatility Over Time: OKYO's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Gary Jacob | okyopharma.com |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
OKYO Pharma Limited Fundamentals Summary
| OKYO fundamental statistics | |
|---|---|
| Market cap | UK£23.22m |
| Earnings (TTM) | -UK£6.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs OKYO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OKYO income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£4.39m |
| Gross Profit | -UK£4.39m |
| Other Expenses | UK£2.31m |
| Earnings | -UK£6.70m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OKYO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/22 01:18 |
| End of Day Share Price | 2023/05/19 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OKYO Pharma Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Ashok Kumar | ThinkEquity LLC |